



## Sage Therapeutics to Present Brexanolone Postpartum Depression Data and SAGE-217 Major Depressive Disorder Data at Upcoming Spring Medical Meetings

April 17, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 17, 2018-- Sage Therapeutics (NASDAQ: SAGE) a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that data from clinical studies of its proprietary i.v. formulation of brexanolone for the treatment of postpartum depression (PPD) as well as SAGE-217, its novel, next-generation positive allosteric modulator of synaptic and extrasynaptic GABA<sub>A</sub> receptors, in major depressive disorder (MDD), will be presented in podium and poster sessions at the following upcoming medical meetings:

### North American Society for Psychosocial Obstetrics and Gynecology (NASPOG)

2018 Biennial Meeting, **April 20-22, 2018 in Philadelphia**

- **Date and Time:** April 20, 2018, 12:15 p.m. – 1:15 p.m. ET
- **Location:** University of Pennsylvania Biomedical Research Building
- **Title:** *Brexanolone iv, a GABAA Receptor Modulator, in the Treatment of Postpartum Depression: Overview of Clinical Studies*

### American College of Obstetricians and Gynecologists (ACOG)

2018 Annual Clinical and Scientific Meeting, **April 27-30, 2018 in Austin, Texas**

- **Date and Time:** April 27, 2018, 1:00 p.m. – 2:00 p.m. CT
- **Location:** Austin Convention Center, Ballroom G
- **Title:** *Phase 3 Study Evaluating Brexanolone, a GABAA Receptor Modulator, in Severe Postpartum Depression*
  
- **Date and Time:** April 28, 2018, 10:15 a.m. – 11:15 a.m. CT
- **Location:** Austin Convention Center, Ballroom G
- **Title:** *Phase 3 Study Evaluating Brexanolone, a GABAA Receptor Modulator, in Moderate Postpartum Depression*

### American Psychiatric Association (APA)

2018 Annual Meeting, **May 5-9, 2018 in New York**

- **Date and Time:** May 7, 2018, 10:00 a.m. – 12:00 p.m. ET
- **Location:** Exhibit Halls 3A/3B, Level 3
- **Title:** *Efficacy and Safety of Brexanolone iv in Hummingbird 202B: A Double-Blind, Placebo-Controlled Phase 3 Study in Severe Postpartum Depression*
  
- **Date and Time:** May 7, 2018, 10:00 a.m. – 12:00 p.m. ET
- **Location:** Exhibit Halls 3A/3B, Level 3
- **Title:** *Efficacy and Safety of Brexanolone iv in Hummingbird 202C: A Double-Blind, Placebo-Controlled Phase 3 Study in Moderate Postpartum Depression*
  
- **Date and Time:** May 7, 2018, 10:00 a.m. – 12:00 p.m. ET
- **Location:** Exhibit Halls 3A/3B, Level 3
- **Title:** *SAGE-217 in Major Depressive Disorder: Results for a First-in-Class GABAA Receptor Allosteric Modulator from a Phase 2 Placebo-Controlled Trial*

### Society of Biological Psychiatry (SOBP)

73<sup>rd</sup> Annual Meeting, **May 10-12, 2018 in New York**

- **Date and Time:** May 12, 2018, 5:00 p.m. – 7:00 p.m. ET
- **Location:** Americas Hall I
- **Title:** *Efficacy and Safety of Brexanolone iv across Phase 2/3 Studies: A First-In-Class GABAA Receptor Positive Allosteric Modulator for Postpartum Depression*
  
- **Date and Time:** May 12, 2018, 4:15 p.m. – 4:30 p.m. ET
- **Location:** Murray Hill East
- **Title:** *SAGE-217 a First in Class GABAA Receptor Positive Allosteric Modulator in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Phase 2 Placebo-Controlled Trial*

### About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, a proprietary IV formulation of brexanolone (SAGE-547), has completed Phase 3 clinical development for postpartum depression. Sage is developing its

next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders. For more information, please visit [www.sagerx.com](http://www.sagerx.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180417006498/en/>

Source: Sage Therapeutics

Sage Therapeutics

**Investor Contact:**

Paul Cox, 617-299-8377

[paul.cox@sagerx.com](mailto:paul.cox@sagerx.com)

or

**Media Contact:**

Maureen L. Suda, 585-355-1134

[maureen.suda@sagerx.com](mailto:maureen.suda@sagerx.com)